EP1371647B1 - Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte - Google Patents

Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte Download PDF

Info

Publication number
EP1371647B1
EP1371647B1 EP03013988A EP03013988A EP1371647B1 EP 1371647 B1 EP1371647 B1 EP 1371647B1 EP 03013988 A EP03013988 A EP 03013988A EP 03013988 A EP03013988 A EP 03013988A EP 1371647 B1 EP1371647 B1 EP 1371647B1
Authority
EP
European Patent Office
Prior art keywords
title compound
preparation
pyridin
ylsulphonyl
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03013988A
Other languages
English (en)
French (fr)
Other versions
EP1371647A2 (de
EP1371647A3 (de
Inventor
Mark Edward Pfizer Central Research Bunnage
John Paul Pfizer Central Research Mathias
Stephen Derek A. Pfizer Central Research STREET
Anthony Pfizer Central Research Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Inc
Original Assignee
Pfizer Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808315.7A external-priority patent/GB9808315D0/en
Priority claimed from GBGB9814187.2A external-priority patent/GB9814187D0/en
Application filed by Pfizer Ltd, Pfizer Inc filed Critical Pfizer Ltd
Priority to SI9930802T priority Critical patent/SI1371647T1/xx
Publication of EP1371647A2 publication Critical patent/EP1371647A2/de
Publication of EP1371647A3 publication Critical patent/EP1371647A3/de
Application granted granted Critical
Publication of EP1371647B1 publication Critical patent/EP1371647B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to a series of pyrazolo[4,3-d]pyrimidin-7-ones, which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds of the invention are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility therefore in a variety of therapeutic areas.
  • the compounds are of value in the treatment of male erectile dysfunction (MED) and female sexual dysfunction (FSD) but, clearly, will be useful also for treating other medical conditions for which a potent and selective cGMP PDE5 inhibitor is indicated.
  • Such conditions include premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency, e.g.
  • post-PTCA post-percutaneous transluminal coronary angioplasty
  • peripheral vascular disease stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).
  • IBS irritable bowel syndrome
  • pre-eclampsia Kawasaki's syndrome, nitrate tolerance, multiple sclerosis, peripheral diabetic neuropathy, stroke, Alzheimer's disease, acute respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and hypoxic vasoconstriction.
  • Particularly preferred conditions include MED and FSD.
  • alkyl, alkoxy and alkenyl groups having three or more carbon atoms, and alkanoyl groups having four or more carbon atoms may be straight chain or branched chain.
  • halo atom includes, Cl, Br, F, and I.
  • Haloalkyl and haloalkoxy are preferably CF 3 and O CF 3 respectively.
  • the compounds of formulae (IA) and (IB) may contain one or more chiral centres and therefore can exist as stereoisomers, i.e. as enantiomers or diastereoisomers, as well as mixtures thereof.
  • the invention includes both the individual stereoisomers of the compounds of formulae (IA) and (IB) and any mixture thereof. Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation or chromatography (including HPLC) of a diastereoisomeric mixture of a compound of formula (IA) or (IB) or a suitable salt or derivative thereof.
  • An individual enantiomer of a compound of formula (IA) or (IB) may be prepared from a corresponding optically pure intermediate or by resolution, either by HPLC of the racemate using a suitable chiral support or, where appropriate, by fractional crystallisation of the diastereoisomeric salts formed by reaction of the racemate with a suitable optically active acid or base.
  • the compounds of formulae (IA) and (IB) may also exist in tautomeric forms and the invention includes both mixtures thereof and the individual tautomers.
  • radiolabelled derivatives of compounds of formulae (IA) and (IB) which are suitable for biological studies.
  • the pharmaceutically or veterinarily acceptable salts of the compounds of formulae (IA) and (IB) which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acid, with carboxylic acids or with organo-sulphonic acids.
  • Compounds of formulae (IA) and (IB) can also provide pharmaceutically or veterinarily acceptable metal salts, in particular non-toxic alkali metal salts, with bases. Examples include the sodium and potassium salts.
  • a preferred group of compounds of formulae (IA) and (IB) is that wherein R 1 is C 1 to C 2 alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R 2 is C 2 to C 4 alkyl; R 13 is OR 3 or NR 5 R 6 ; R 3 is C 1 to C 4 alkyl optionally substituted with one or two substituents selected from cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, benzyloxy, NR 5 R 6 , phenyl, furan-3-yl, pyridin-2-yl and pyridin-3-yl; cyclobutyl; 1-methylpiperidin-4-yl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R 5 and R 6 are each independently selected from H and C 1 to C 2 alkyl optionally substituted with cyclopropyl or meth
  • a more preferred group of compounds of formulae (IA) and (IB) is that wherein R 1 is C 1 to C 2 alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R 2 is C 2 to C 4 alkyl; R 13 is OR 3 ; R 3 is C 1 to C 4 alkyl optionally monosubstituted with cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, phenyl, furan-3-yl or pyridin-2-yl; cyclobutyl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R 7 and R 8 , together with the nitrogen atom to which they are attached, form a 4-R 10 -piperazinyl group optionally in the form of its 4-N-oxide; R 10 is C 1 to C 3 alkyl optionally monosubstituted with OH; and Het is selected from
  • Particularly preferred individual compounds of the invention include 3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 3-ethyl-5-[5-(4-ethylpiperazin-1-yisulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydr
  • R 1 is not unsubstituted C 1 alkyl; the optional substituent on the C 1 alkyl group of R 1 is not a substituted phenyl group or a N-linked heterocyclic group; the optional substituent on the C 2 or C 3 alkyl group of R 1 is not phenyl or Het; or wherein R 13 is not NR 5 R 6 ; or wherein the alkyl group of R 3 is not C 5 or C 6 ; or wherein the optional substituent on R 3 is not C 3 to C 5 cycloalkyl; or wherein neither the alkyl or the optional alkoxy substituents on R 3 are terminated by a haloalkyl group; or wherein the C 1 to C 4 alkyl groups of R 5 and R 6 are not substituted by C 3 to C 5 cycloalkyl or C 1 to C 4 alkoxy; or wherein
  • the present invention provides processes for the preparation of compounds of formulae (IA) and (IB), their pharmaceutically and veterinarily acceptable salts, and pharmaceutically and veterinarily acceptable solvates of either entity, as illustrated below.
  • Illustrative of a protecting group strategy is the route to the 2 1 -(2-hydroxyethoxy) analogue (Example 33), the precursor to which (Example 32) contains benzyl as the alcohol-protecting group.
  • vanous standard substituent or functional group interconversions and transformations within certain compounds of formulae (IA) and (IB) will provide other compounds of formulae (IA) and (IB).
  • Examples include alkoxide exchange at the 2-position of the 5-(pyridin-3-yl) substituent (see conversions of Example 1 to Examples 4B, 9, 11, 13, 23, 24, 32 and 64, Example 2 to Example 14, Example 20 to Example 21, Example 26 to Examples 29, 65, 66, 67 and 68, Example 35 to Example 36, Example 38 to Examples 39 and 40, and Example 45 to Example 46), amine exchange at the 2-position of the 5-(pyridin-3-yl) substituent (see conversions of Example 78 to Examples 148 and 154) and piperazine and/or pyridine N-oxidation (see conversions of Example 1 to Example 70, Example 28 to Example 71, and Example 4 to Examples 72 and 73).
  • a compound of formula (IA) or (IB) may be prepared by alkylation of a compound of formula (IA) or (IB) wherein R 1 is hydrogen and R 2 , R 13 and R 4 are as previously defined for formulae (IA) and (IB), using one or more of a plethora of well-known methods, such as:
  • a 10% excess of sodium hydride is added to a solution of the substrate in a suitable solvent, e.g. anhydrous tetrahydrofuran, and the resulting anion treated with about a 10% excess of the required R 1 X.
  • a suitable solvent e.g. anhydrous tetrahydrofuran
  • a compound of formula (IA) or (IB) wherein R 1 is hydrogen and R 2 , R 13 and R 4 are as previously defined for formulae (IA) and (IB) may be obtained from a compound of formula (IXA) or (IXB) respectively wherein R 1 is hydrogen and R 2 , R 13 and R 4 are as previously defined for formulae (IXA) and (IXB), under the same conditions as those used for the conversion of a compound of formula (IXA) or (IXB) to a compound of formula (IA) or (IB) respectively when R 1 is other than hydrogen, followed by acidification of the reaction mixture to a pH of about 6.
  • the amines of formula (III), the 4-aminopyrazole-5-carboxamides of formulae (VIIA) and (VIIB), the carboxylic acids of formulae (VIII) and (X), the nitriles of formula (XIII) and the esters of formula (XVI), when neither commercially available nor subsequently described, can be obtained either by analogy with the processes described in the Preparations section or by conventional synthetic procedures, in accordance with standard textbooks on organic chemistry or literature precedent, from readily accessible starting materials using appropriate reagents and reaction conditions.
  • the pharmaceutically acceptable acid addition salts of the compounds of formulae (IA) and (IB) which contain a basic centre may also be prepared in a conventional manner. For example a solution of the free base is treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration of by evaporation under vacuum of the reaction solvent.
  • Base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (IA) or (IB) with the appropriate base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
  • the biological activities of the compounds of the present invention were determined by the following test methods.
  • Phosphodiesterase (PDE) inhibitory activity Phosphodiesterase (PDE) inhibitory activity
  • the required PDE enzymes were isolated from a variety of sources, including human corpus cavernosum, human and rabbit platelets, human cardiac ventricle, human skeletal muscle and bovine retina, essentially by the method of W.J. Thompson and M.M. Appleman (Biochem., 1971, 10 , 311).
  • the cGMP-specific PDE (PDE5) and the cGMP-inhibited cAMP PDE (PDE3) were obtained from human corpus cavemosum tissue, human platelets or rabbit platelets; the cGMP-stimulated PDE (PDE2) was obtained from human corpus cavernosum; the calcium/calmodulin (Ca/CAM)-dependent PDE (PDE1) from human cardiac ventricle; the cAMP-specific PDE (PDE4) from human skeletal muscle; and the photoreceptor PDE (PDE6) from bovine retina.
  • the compounds of formulae (IA) and (IB), their pharmaceutically acceptable salts, and pharmaceutically acceptable solvates of either entity can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • they are administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents.
  • They can also be injected parenterally, for example intracavemosally, intravenously, intramuscularly or subcutaneously.
  • parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
  • buccal or sublingual administration they may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
  • the compounds may also be administered intranasally or formulated for dermal application.
  • the daily dosage level of the compounds of formulae (IA) and (IB) and their pharmaceutically acceptable salts and solvates may be from 10 to 500 mg (in single or divided doses).
  • tablets or capsules may contain from 5 to 250 mg of active compound for administration singly, or two or more at a time, as appropriate.
  • the physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
  • compounds of the invention may be taken as a single dose on an "as required" basis (i.e. as needed or desired).
  • oral administration of the compounds of the invention is the preferred route, being the most convenient and, for example in MED, avoiding the well-known disadvantages associated with intracavernosal (i.c.) administration.
  • a preferred oral dosing regimen in MED for a typical man is from 25 to 250 mg of compound when required.
  • the drug may be administered parenterally, sublingually or buccally.
  • a compound of formula (IA) or (IB), or a veterinarily acceptable salt thereof, or a veterinarily acceptable solvate of either entity is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, together with a pharmaceutically acceptable diluent or carrier.
  • a veterinary formulation comprising a compound of formula (IA) or (IB), or a veterinarily acceptable salt thereof, or a veterinarily acceptable solvate of either entity, together with a veterinarily acceptable diluent or carrier.
  • the invention also provides a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, for use as a human medicament.
  • the invention provides the use of a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, for the manufacture of a human medicament for the curative or prophylactic treatment of a medical condition for which a cGMP PDE5 inhibitor is indicated.
  • a compound of formula (IA) or (IB) or a suitable salt or solvate thereof in the manufacture of a medicament for the treatment of a medical condition in which inhibition of a cGMP PDE5 is desirable.
  • the invention provides the use of a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate containing either entity, for the manufacture of a human medicament for the curative or prophylactic treatment of male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, (e.g.
  • post-PTCA post transluminal coronary angioplasty
  • chronic asthma bronchitis
  • allergic asthma allergic rhinitis
  • glaucoma diseases characterised by disorders of gut motility
  • IBS irritable bowel syndrome
  • Other conditions which may be mentioned include pre-eclampsia, Kawasaki's syndrome, nitrate tolerance, multiple sclerosis, peripheral diabetic neuropathy, stroke, Alzheimer's disease, acute respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and hypoxic vasoconstriction.
  • Particularly preferred conditions include MED and FSD.
  • a compound of formula (IA) or (IB), or a veterinarily acceptable salt thereof, or a veterinarily acceptable solvate containing either entity for the manufacture of an animal medicament for the curative or prophylactic treatment of male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Pnnzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency (e.g.
  • the invention provides a method of treating or preventing a medical condition for which a cGMP PDE5 inhibitor is indicated, in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (IA) or (IB), or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, or a pharmaceutical composition or veterinary formulation containing any of the foregoing.
  • a mammal including a human being
  • the invention provides a method of treating or preventing male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency (e.g.
  • the invention also includes any novel intermediates described herein, for example those of formulae (IIA), (IIB), (IVA), (IVB), (IXA), (IXB), (VA) and (VB).
  • Mass spectra (m/z) were recorded using a Fisons Instruments Trio mass spectrometer in the thermospray ionisation mode.
  • Room temperature means 20 to 25°C.
  • the organic phase was separated, combined with a dichloromethane extract (20ml) of the aqueous phase, dried (MgSO 4 ) and evaporated under reduced pressure.
  • the residual yellow foam was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, followed by HPLC using a 5 ⁇ m Spherisorb silica column with water: acetonitrile: diethylamine (50:50:0.1) as eluant at a rate of 1 ml/min, to give the title compound (30mg, 17%) as a white foam.
  • Triethylamine (83 ⁇ l, 0.59mmol) and 1-methylpiperazine (36mg, 0.356mmol) were added to a stirred, ice-cooled suspension of the title compound of Preparation 64 (150mg, 0.30mmol) in dichloromethane (10ml) and the reaction mixture stirred for 2 hours at room temperature.
  • the crude product was purified by two column chromatography operations on silica gel, using firstly dichloromethane: methanol:0.88 aqueous ammonia (90:10:1) and then a gradient of ethyl acetate: methanol (100:0 to 80:20) as eluants, to yield the title compound as an oil.
  • LRMS m/z 568 (M+1) + ; followed by the second title compound (2-isomer; 20mg) as a white solid.
  • LRMS m/z 568 (M+1) + .
  • the residual yellow oil was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: methanol (90:10 to 80:20), to yield the title compound (33mg, 30%) as a white solid.
  • 3-Chlorobenzoic acid (15mg, 0.096mmol) was added to a stirred solution of the title compound of Example 4 (223mg, 0.38mmol) in dichloromethane (3ml) and the mixture stirred at room temperature for 30 minutes.
  • 3-Chloroperoxybenzoic acid (132mg, 0.38mmol) was then added and the reaction mixture stirred at room temperature for 14 hours, then partitioned between dichloromethane (5ml) and aqueous sodium bicarbonate solution (5ml). The phases were separated, the aqueous phase extracted with dichloromethane (3x10ml) and the combined organic solutions dried (MgSO 4 ) and evaporated under reduced pressure.
  • Example 78 The title compound of Example 78 (400mg, 0.84mmol) was added to a mixture of potassium bis(trimethylsilyl)amide (840mg, 4.2mmol) in ( R )-2-butanol (4ml) and the mixture stirred at 110°C for 18 hours. The cooled mixture was concentrated under reduced pressure and the residue suspended in water (10ml) and neutralised using 2N hydrochloric acid. This aqueous suspension was extracted with ethyl acetate (3x30ml), the combined organic extracts washed with sodium hydroxide solution (20ml), brine (2x30ml), dried (Na 2 SO 4 ) and evaporated under reduced pressure.
  • Example 78 The title compound of Example 78 (100mg, 0.2mmol) and potassium bis(trimethylsilyl)amide (121mg, 0.61mmol) in the intermediate alcohol (1ml), was heated at 110°C for 30 hours, then the reaction cooled and concentrated under reduced pressure.
  • the residual brown solid was purified by column chromatography on silica gel using diethylamine: ethyl acetate (5:95) as eluant, and repeated using methanol: ethyl acetate (5:95) as eluant.
  • the product was triturated with ether to afford the title compound (7mg, 6%) as a white solid.
  • Example 79 The title compound of Example 79 (198mg, 0.42mmol) was added to a solution of potassium bis(trimethylsilyl)amide (415mg, 2.1 mmol) in 1-methoxy-2-propanol (5ml), and the reaction heated at 110°C for 72 hours. The cooled mixture was evaporated under reduced pressure, the residue dissolved in water and neutralised using 2M hydrochloric acid This aqueous solution was extracted with ethyl acetate (3x30ml), the combined organic extracts washed with brine (3x20ml), dried (Na 2 SO 4 ) and evaporated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 97:3), and evaporated from ether to give a white solid.
  • the racemic product was purified by chiral HPLC using an AD250 column, and hexane: isopropanol:trifluoroacetic acid (80:20:0.5) as eluant.
  • the first enantiomer was redissolved in water, basified using aqueous sodium carbonate solution, and this mixture extracted with ethyl acetate (3x20ml).
  • the combined organic extracts were washed with brine (2x20ml) dried (Na 2 SO 4 ) and evaporated under reduced pressure.
  • LRMS m/z 520 (M+1) +
  • the first enantiomer was partitioned between dichloromethane (20ml) and aqueous sodium carbonate solution (10ml), the phases separated, and the organic layer dried (Na 2 SO 4 ), and evaporated under reduced pressure.
  • the product was further purified by column chromatography on silica gel, using ethyl acetate: methanol (95:5) as eluant, to afford the title compound of Example 106 (130mg, 16%, 99.76%ee) as a white foam.
  • Example 78 The title compounds were prepared from the title compound of Example 78, and 2-methoxy-1-propanol following a similar procedure to that described for Examples 104 and 105.
  • the racemate was further purified by HPLC using an AD250 column and hexane: ethanol:diethylamine (60:40:1) as eluant, to give isomer 1.
  • This product was re-purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 97:3) and triturated with ether to afford the title compound of Example 108 (8mg, 2%, 82%ee) as a white solid.
  • the racemate was prepared (70%) from the title compound of Example 78 and 1-ethoxy-2-propanol, following the procedure described for Examples 104 and 105.
  • Example 116 and 117 were obtained as solids, (4%, 99.0%ee) and (2%, 99.0%ee) respectively, from the title compound of Example 78 and 1-(pyridin-2-yl) ethanol (Helv.Chim.Acta., 1955, 38 , 1114), following a similar procedure to that described for Examples 112 and 113, except that hexane: isopropanol: diethylamine (70:30:1) was used as the HPLC eluant.
  • Example 124 The title compounds of Examples 128 and 129 were prepared from Example 124 (17%, 99.5%ee) and (15%, 98.6%ee) respectively, following a procedure similar to that described in Examples 106 and 107, except that hexane :isopropanol : diethylamine :trifluoroacetic acid (85:15:0.2:0.3) was used as the HPLC eluant.
  • Example 144 (24mg, 11%, 100.0%ee) ⁇ (CDCl 3 ) : 1.02 (3H, t), 1.25 (3H, t), 2.10 (3H, d), 2.40 (2H, q), 2.56 (4H, m), 3.00 (2H, q), 3.13 (4H, m), 3.58 (3H, s), 3.86 (2H, t), 4.77 (2H, t), 5.83 (1H, q), 7.18 (2H, m), 7.60 (1H, m), 8.55 (1H, d), 8.60 (1H, s), 8.96 (1H, s),
  • the crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 to 99.6:0.4:0.5) to afford the title compound (50mg, 59%) as a white foam.
  • Ammonium nitrate (10.57g, 131mmol) was added portionwise to a stirred, ice-cooled solution of the title compound of Preparation 4 (14.80g, 65.7mmol) in trifluoroacetic anhydride (150ml) and the reaction mixture stirred for 3 hours at room temperature, then carefully poured onto stirred ice (120g). The resulting solution was extracted with dichloromethane (3x150ml), then the combined extracts dried (MgSO 4 ) and evaporated under reduced pressure.
  • Triethylamine (3ml, 19mmol) and tetrakis (triphenylphosphine) palladium (0) (260mg, 0.22mmol) were added to a solution of the title compound of Preparation 14 (1.30g, 3mmol) in ethanol (15ml) and the mixture heated under carbon monoxide at 100°C and 1034 kPa (150psi) in a sealed vessel for 18 hours, then allowed to cool. The reaction mixture was filtered and the filtrate evaporated under reduced pressure to provide a yellow solid.
  • Oxalyl chloride (0.77ml, 8.85mmol) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation 23 (1.52g, 4.42mmol) and dimethylformamide (2 drops) in dichloromethane (30ml) and the reaction mixture stirred for 18 hours at room temperature, then evaporated under reduced pressure. The residue was triturated with ethyl acetate and the resulting solid collected, washed with ether and dried under suction to afford the title compound (1.68g, 95%). Found C, 41.51; H, 5.27; N, 10.32. C 14 H 21 Cl 2 N 3 O 4 S; 0.10 CH 2 Cl 2 requires C, 41.73; H, 5.02; N, 10.36%.
  • Oxalyl chloride (270 ⁇ l, 3.13mmol) was added dropwise to a stirred, ice-cooled suspension of the title compound of Preparation 25 (390mg, 1.04mmol), dimethylformamide (100 ⁇ l) and dry dichloromethane (20ml), then the reaction mixture stirred for 3 hours at room temperature. The resulting mixture was evaporated under reduced pressure and the residue azeotroped with toluene (2 x 20ml) to give the title compound (390mg, 95%) as a white solid.
  • Ethanolic sodium ethoxide solution (21% w/w; 143ml, 0.39mol) was added dropwise to a stirred, ice-cooled solution of diethyl oxalate (59.8ml, 0.44mol) in absolute ethanol (200ml) under nitrogen and the resulting solution stirred for 15 minutes.
  • Butan-2-one 39ml, 0.44mol was then added dropwise, the cooling bath removed, the reaction mixture stirred for 18 hours at room temperature and then for 6 hours at 40°C, then the cooling bath reintroduced.
  • Aqueous sodium hydroxide solution (10M; 100ml, 1.0mol) was added dropwise to a stirred suspension of the title compound of Preparation 30 (66.0g, 0.39mol) in methanol (400ml) and the resulting solution heated under reflux for 4 hours.
  • the cool reaction mixture was concentrated under reduced pressure to ca . 200ml, diluted with water (200ml) and this mixture washed with toluene (3x100ml).
  • the resulting aqueous phase was acidified with concentrated hydrochloric acid to pH 4 and the white precipitate collected and dried by suction to provide the title compound (34.1g).
  • Fuming sulphuric acid (17.8ml) was added dropwise to stirred, ice-cooled fuming nitric acid (16.0ml), the resulting solution heated to 50°C, then 3-n-propyl-1H-pyrazole-5-carboxylic acid (Chem. Pharm. Bull., 1984, 32 , 1568; 16.4g, 0.106mol) added portionwise over 30 minutes whilst maintaining the reaction temperature below 60°C.
  • the resulting solution was heated for 18 hours at 60°C, allowed to cool, then poured onto ice. The white precipitate was collected, washed with water and dried by suction to yield the title compound (15.4g), m.p. 170-172°C.
  • Oxalyl chloride (2.73ml, 31mmol) was added dropwise to a stirred suspension of the title compound of Preparation 8 (3.31g, 15.7mmol) in dichloromethane (50ml), followed by dimethylformamide (2 drops), and the reaction mixture stirred at room temperature for 3 hours. The resulting mixture was evaporated under reduced pressure and the residue azeotroped with hexane to give a white solid.
  • Oxalyl chloride (122 ⁇ l, 5.6mmol) was added dropwise to a stirred solution of the title compound of Preparation 79 (478mg, 1.4mmol) and dimethylformamide (3 drops) in dichloromethane (10ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was azeotroped with dichloromethane (3x10ml), then added to a stirred, ice-cooled solution of the title compound of Preparation 41 (360mg, 1.4mmol) in pyridine (10ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure.
  • Zinc chloride (820mg, 6mmol) was added to a stirred mixture of benzaldehyde (6.11 ml, 60mmol) and 3-methylpyridazine (2.83g, 30mmol) and the resulting mixture heated for 20 hours at 150°C.
  • the cool reaction mixture was partitioned between dichloromethane (40ml) and 2M aqueous sodium hydroxide solution (20ml), then the organic phase separated, combined with a dichloromethane extract (80ml) of the aqueous phase, dried (Na 2 SO 4 ) and evaporated under reduced pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

  1. Verbindung der Formel (X)
    Figure 02070001
       worin
       R13 OR3 darstellt, worin R3 C1-C4-Alkyl, gegebenenfalls substituiert mit einem oder zwei Substituenten, ausgewählt aus OH, C1-C4-Alkoxy, Benzyloxy, NR5R6, Phenyl, Furanyl und Pyridinyl; C3-C6-Cycloalkyl; 1-(C1-C4-Alkyl)piperidinyl; Tetrahydrofuranyl oder Tetrahydropyranyl
       R4 SO2NR7R8 darstellt;
       R5 und R6 jeweils unabhängig aus H und C1-C4-Alkyl,
       ausgewählt sind oder zusammen mit dem Stickstoffatom, an das sie gebunden sind, eine Pyrrolidinyl-, Piperidinyl- oder Morpholinylgruppe darstellen;
       R7 und R8 zusammen mit dem Stickstoffatom, an das sie gebunden sind, eine 4-R10-Piperazinylgruppe, gegebenenfalls substituiert mit einer oder zwei C1-C4-Alkylgruppen, und gegebenenfalls in Form ihres 4-N-Oxids, bilden; und
       R10 H; C1-C4-Alkyl, gegebenenfalls substituiert mit einem oder zwei Substituenten, ausgewählt aus OH, NR5R6, CONR5R6, Phenyl, gegebenenfalls substituiert mit C1-C4-Alkoxy, Benzodioxolyl und Benzodioxanyl; C3-C6-Alkenyl; Pyridinyl oder Pyrimidinyl darstellt; oder ein Salz einer solchen Verbindung, oder ein Saurechloridderivat von einer solchen Verbindung.
  2. Verbindung nach Anspruch 1, worin R13 OR3 darstellt, R3 C1-C4-Alkyl, gegebenenfalls monosubstituiert mit OH, Methoxy, Ethoxy, Phenyl, Furan-3-yl oder Pyridin-2-yl; Cyclobutyl; Tetrahydrofuran-3-yl oder Tetrahydropyran-4-yl, darstellt; R7 und R8 zusammen mit dem Stickstoffatom, an das sie gebunden sind, eine 4-R10-Piperazinylgruppe, gegebenenfalls in Form ihres 4-N-Oxids, bilden; und R10 C1-C3-Alkyl, gegebenenfalls monosubstituiert mit OH, darstellt.
  3. Verbindung nach Anspruch 1 oder 2, ausgewählt aus:
    2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-carbonsäure;
    2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-carbonsäure-Natriumsalz;
    4-(4-Ethylpiperazin-1-ylsulfonyl)-2-(2-methoxyethoxy)pyridin-3-carbonsäure-Hydrochlorid;
    2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulfonyl)pyridin-3-carbonsäure-Hydrochlorid;
    5-(4-Ethylpiperazin-1-ylsulfonyl)-2-(3-methoxyprop-1-oxy)pyridin-3-carbonsäure-Hydrochlorid;
    2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-pyridin-3-carbonsäure-Hydrochlorid; und
    5-(4-Ethylpiperazin-1-ylsulfonyl)-2-(2-methoxyethoxy)-pyridin-3-carbonsaure-Hydrochlorid.
  4. 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)-pyridin-3-carbonsäure nach Anspruch 1 oder 2.
EP03013988A 1998-04-20 1999-03-25 Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte Expired - Lifetime EP1371647B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9930802T SI1371647T1 (en) 1998-04-20 1999-03-25 Pyridine-3-carboxylic acid derivatives and their use as intermediates

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9808315 1998-04-20
GBGB9808315.7A GB9808315D0 (en) 1998-04-20 1998-04-20 Therapeutic agents
GBGB9814187.2A GB9814187D0 (en) 1998-06-30 1998-06-30 Therapeutic agents
GB9814187 1998-06-30
EP99907805A EP1073658B1 (de) 1998-04-20 1999-03-25 Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP99907805A Division EP1073658B1 (de) 1998-04-20 1999-03-25 Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen

Publications (3)

Publication Number Publication Date
EP1371647A2 EP1371647A2 (de) 2003-12-17
EP1371647A3 EP1371647A3 (de) 2004-07-28
EP1371647B1 true EP1371647B1 (de) 2005-07-13

Family

ID=26313490

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03013988A Expired - Lifetime EP1371647B1 (de) 1998-04-20 1999-03-25 Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
EP99907805A Expired - Lifetime EP1073658B1 (de) 1998-04-20 1999-03-25 Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99907805A Expired - Lifetime EP1073658B1 (de) 1998-04-20 1999-03-25 Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen

Country Status (40)

Country Link
US (2) US6251904B1 (de)
EP (2) EP1371647B1 (de)
JP (2) JP3721077B2 (de)
KR (1) KR100449790B1 (de)
CN (2) CN1229349C (de)
AP (1) AP1022A (de)
AR (2) AR015770A1 (de)
AT (2) ATE247117T1 (de)
AU (1) AU748352B2 (de)
BG (1) BG104949A (de)
BR (1) BR9909808A (de)
CA (1) CA2329077C (de)
CO (1) CO5271649A1 (de)
DE (2) DE69926154T2 (de)
DK (2) DK1371647T3 (de)
DZ (1) DZ2773A1 (de)
EA (1) EA200000969A1 (de)
ES (2) ES2203078T3 (de)
GT (1) GT199900053A (de)
HK (1) HK1064670A1 (de)
HR (1) HRP20000712A2 (de)
HU (1) HUP0102543A3 (de)
ID (1) ID27036A (de)
IL (2) IL138907A0 (de)
IS (1) IS5650A (de)
MA (1) MA26622A1 (de)
NO (1) NO20005255L (de)
OA (1) OA11502A (de)
PA (1) PA8470501A1 (de)
PE (1) PE20000463A1 (de)
PL (1) PL343794A1 (de)
PT (2) PT1073658E (de)
RS (1) RS50011B (de)
SI (2) SI1073658T1 (de)
SK (1) SK15532000A3 (de)
TN (1) TNSN99073A1 (de)
TR (1) TR200003039T2 (de)
TW (1) TW593310B (de)
UY (1) UY25484A1 (de)
WO (1) WO1999054333A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723719B1 (en) 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EP1371647B1 (de) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6242444B1 (en) 1999-06-04 2001-06-05 The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. Compounds and pharmaceutical compositions containing the same
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
US6350751B1 (en) 1999-10-11 2002-02-26 Pfizer Inc. Therapeutic agents
NZ517324A (en) * 1999-10-11 2003-09-26 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
CA2407031A1 (en) * 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6667398B2 (en) * 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (de) * 2000-07-28 2002-01-30 Pfizer Inc. Verfahren zur Herstellung von Pyrazolen
ES2231521T3 (es) * 2000-07-28 2005-05-16 Pfizer Inc. Agente terapeutico cristalino.
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US6420557B1 (en) * 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005079808A1 (en) 2004-01-22 2005-09-01 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US7618972B2 (en) 2005-03-21 2009-11-17 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
CN101163476A (zh) 2005-04-19 2008-04-16 尼科梅德有限责任公司 用于治疗肺动脉高血压的罗氟司特
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2379076B1 (de) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase-hemmer und ihre verwendungen
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
EP3099689B1 (de) * 2014-01-30 2022-01-26 Council of Scientific and Industrial Research Pyrazolpyrimidinone für die behandlung von impotenz und verfahren zur herstellung davon
CN103922960B (zh) * 2014-04-16 2015-10-21 浙江中山化工集团股份有限公司 一种s-异丙甲草胺的合成方法
CN104402811A (zh) * 2014-11-11 2015-03-11 常州大学 一种合成二甲氨基吡啶甲酸的方法
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
KR20210028144A (ko) * 2018-04-06 2021-03-11 블랙 벨트 티엑스 리미티드 Atf6 저해제 및 그의 용도
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (de) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidinverbindungen als alk2 und/oder fgfr-modulatoren
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
KR19980702892A (ko) 1995-03-10 1998-08-05 보먼 메리 피 6-아릴 피라졸로[3,4-디]피리미딘-4-온 및 그의 조성물 및 그의사용 방법
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6723719B1 (en) * 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
EP1371647B1 (de) 1998-04-20 2005-07-13 Pfizer Inc. Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
WO1999054333A1 (en) 1999-10-28
DK1371647T3 (da) 2005-10-17
DE69926154T2 (de) 2006-03-23
DE69910368D1 (de) 2003-09-18
DE69910368T2 (de) 2004-03-25
HUP0102543A3 (en) 2002-01-28
KR100449790B1 (ko) 2004-09-22
IS5650A (is) 2000-09-29
BG104949A (en) 2001-06-29
ATE247117T1 (de) 2003-08-15
DK1073658T3 (da) 2003-12-08
BR9909808A (pt) 2000-12-26
ATE299503T1 (de) 2005-07-15
ES2242124T3 (es) 2005-11-01
CO5271649A1 (es) 2003-04-30
GT199900053A (es) 2000-10-04
PT1073658E (pt) 2003-12-31
TW593310B (en) 2004-06-21
ES2203078T3 (es) 2004-04-01
CN1229349C (zh) 2005-11-30
SI1073658T1 (en) 2003-12-31
JP3721077B2 (ja) 2005-11-30
PT1371647E (pt) 2005-10-31
CA2329077C (en) 2007-09-18
CN1134442C (zh) 2004-01-14
TR200003039T2 (tr) 2001-01-22
CA2329077A1 (en) 1999-10-28
PE20000463A1 (es) 2000-05-26
AP9901514A0 (en) 1999-06-30
RS50011B (sr) 2008-09-29
EP1073658B1 (de) 2003-08-13
YU63500A (sh) 2002-11-15
IL138907A0 (en) 2001-11-25
SK15532000A3 (sk) 2001-12-03
AR015770A1 (es) 2001-05-16
HUP0102543A2 (hu) 2001-11-28
NO20005255D0 (no) 2000-10-19
EP1371647A2 (de) 2003-12-17
HRP20000712A2 (en) 2001-06-30
AP1022A (en) 2001-11-14
EA200000969A1 (ru) 2001-06-25
JP2002512248A (ja) 2002-04-23
EP1371647A3 (de) 2004-07-28
AU748352B2 (en) 2002-06-06
IL138907A (en) 2007-08-19
JP2004099620A (ja) 2004-04-02
OA11502A (en) 2004-05-10
PL343794A1 (en) 2001-09-10
MA26622A1 (fr) 2004-12-20
US20010039271A1 (en) 2001-11-08
TNSN99073A1 (fr) 2005-11-10
KR20010042815A (ko) 2001-05-25
CN1495169A (zh) 2004-05-12
AU2742599A (en) 1999-11-08
CN1305478A (zh) 2001-07-25
ID27036A (id) 2001-02-22
US6251904B1 (en) 2001-06-26
US6458951B2 (en) 2002-10-01
HK1064670A1 (en) 2005-02-04
DE69926154D1 (de) 2005-08-18
NO20005255L (no) 2000-12-19
AR057934A2 (es) 2007-12-26
EP1073658A1 (de) 2001-02-07
SI1371647T1 (en) 2005-10-31
PA8470501A1 (es) 2000-09-29
DZ2773A1 (fr) 2003-12-01
UY25484A1 (es) 1999-11-17

Similar Documents

Publication Publication Date Title
EP1371647B1 (de) Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
DE69925970T2 (de) Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion
EP1220856B1 (de) Pyrazolo[4,3-d]pyrimidinderivate
KR100404256B1 (ko) 피-38 엠에이피 키나제 저해제로서의 피라졸 유도체
EP1123296B1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
EP1377556B1 (de) Pyrazolderivate zur behandlung von hiv
EP0995750A1 (de) Pyrazolopyrimidinone, CGMP PDE5 Inhibitoren, zur Behandlung von sexuellen Funktionsstörungen
OA11168A (en) Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
JP2003509495A (ja) ピラゾール誘導体
JP2001019672A (ja) 掻痒症の治療用の新規な４−アリールピペリジン誘導体
MXPA00010388A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
CZ20003882A3 (cs) Pyrazolpyrimidinové inhibitory CGMP PDE5 pro léčbu sexuálních dysfunkcí
UA72773C2 (en) Pyrazole [4,3-d] pyrimidine derivatives, a method for the preparation thereof, intermediary compounds, pharmaceutical and veterinary compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030620

AC Divisional application: reference to earlier application

Ref document number: 1073658

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 405/12 B

Ipc: 7C 07D 213/80 B

Ipc: 7C 07D 401/12 A

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AXX Extension fees paid

Extension state: RO

Payment date: 20030620

Extension state: LT

Payment date: 20030620

Extension state: AL

Payment date: 20030620

Extension state: LV

Payment date: 20030620

Extension state: MK

Payment date: 20030620

Extension state: SI

Payment date: 20030620

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER LIMITED

Owner name: PFIZER INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

17Q First examination report despatched

Effective date: 20050422

AC Divisional application: reference to earlier application

Ref document number: 1073658

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69926154

Country of ref document: DE

Date of ref document: 20050818

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050402222

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Effective date: 20050906

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2242124

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060418

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: PFIZER INC.

Free format text: PFIZER INC.#235 EAST 42ND STREET#NEW YORK, N.Y. 10017 (US) -TRANSFER TO- PFIZER INC.#235 EAST 42ND STREET#NEW YORK, N.Y. 10017 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20071228

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080317

Year of fee payment: 10

Ref country code: DK

Payment date: 20080212

Year of fee payment: 10

Ref country code: CH

Payment date: 20080108

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080322

Year of fee payment: 10

Ref country code: PT

Payment date: 20080103

Year of fee payment: 10

Ref country code: SE

Payment date: 20080310

Year of fee payment: 10

Ref country code: IE

Payment date: 20080123

Year of fee payment: 10

Ref country code: NL

Payment date: 20080219

Year of fee payment: 10

Ref country code: FI

Payment date: 20080229

Year of fee payment: 10

Ref country code: GB

Payment date: 20080211

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20080206

Year of fee payment: 10

Ref country code: AT

Payment date: 20080211

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20080331

Year of fee payment: 10

Ref country code: FR

Payment date: 20080307

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20080403

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080116

Year of fee payment: 10

BERE Be: lapsed

Owner name: *PFIZER INC.

Effective date: 20090331

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20090925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090925

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090325

LTLA Lt: lapse of european patent or patent extension

Effective date: 20090325

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20091001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091001

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20091215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091123

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090326